Last update 01 Nov 2024

Mural Oncology, Inc.

Subsidiary Company|
Massachusetts, United States

Overview

Tags

Neoplasms
Endocrinology and Metabolic Disease
Digestive System Disorders
Interleukins
Recombinant polypeptide

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Recombinant polypeptide1
Interleukins1
Top 5 TargetCount
IL-18(Interleukin 18)1
IL-2R(Interleukin-2 receptor)1

Related

2
Drugs associated with Mural Oncology, Inc.
Nemvaleukin Alfa
Target
IL-2R
Mechanism
IL-2R agonists
Active Org.
Mural Oncology, Inc. [+2]
Originator Org.
Alkermes PlcAlkermes Plc
Active Indication
Fallopian Tube Carcinoma [+8]
Inactive Indication
Colonic Cancer [+1]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
WO2024102587
Patent Mining
Target
IL-18
Mechanism-
Active Org.
Mural Oncology, Inc.
Originator Org.
Mural Oncology, Inc.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
5
Clinical Trials associated with Mural Oncology, Inc.
NCT04830124
/ RecruitingPhase 2
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
NCT04592653
/ Active, not recruitingPhase 1/2
Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3
NCT04144517
/ CompletedPhase 2
A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
100 Clinical Results associated with Mural Oncology, Inc.
Login to view more data
0 Patents (Medical) associated with Mural Oncology, Inc.
Login to view more data
100 Deals associated with Mural Oncology, Inc.
Login to view more data
100 Translational Medicine associated with Mural Oncology, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Nemvaleukin Alfa
 ( IL-2R )		Mucosal Melanoma
More
Phase 2
WO2024102587
 ( IL-18 )		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free